PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany - Gyorgi Keri, Professor, CEO & CSO at Vichem Chemie Research Ltd will give a presentation titled “Developing Kinase Inhibitors for Personalized Therapy,” at the Protein Kinases in Drug Discovery Conference Europe in Berlin, Germany on May 8-9, 2014 by GTC
Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/12/15 - Gyorgi Keri, Professor, CEO & CSO at Vichem Chemie Research Ltd will give a presentation titled “Developing Kinase Inhibitors for Personalized Therapy,” at the Protein Kinases in Drug Discovery Conference Europe in Berlin, Germany on May 8-9, 2014 by GTC.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gyorgi Keri is the founder of Vichem Chemie Res. Ltd and is a Professor at Semmelweis University. He got his PhD from biochemistry in Budapest, and was post doc. at University of California, San Francisco.

He has been working together with Professor Axel Ullrich (Max Planck Institute) for more than 25 years on developing kinase inhibitors. He was advisor and collaborative partner of SUgen Inc. from 1992 to 1999 and Axxima Pharmaceuticals from 1999 to 2005.

He has been involved in the development of several kinase inhibitors which have been licensed for external partners. He also developed the Nested Chemical Library™ (NCL) technology, based on a knowledge based approach where focused libraries of kinase inhibitors around more than 600 scaffolds are used for hit finding and to generate pharmacophore models.

Using the NCL™ kinase inhibitor library, Vichem has developed, and will further develop, kinase inhibitors which kill more than 95% of certain cancer cells (including cancer stem cells). The goal is to provide a personalized therapy and molecular diagnostic protocol to select who will respond to a particular cancer stem cell killing drug.

The Protein Kinases in Drug Discovery Conference Europe, to be held on May 8-9, 2014, in Berlin, Germany, will be a premier conference that will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on drug discovery aspects within the protein kinases field. A balance of both academic and industry experts will facilitate discussion on validation of novel drug targets, current progress in drug design, kinases inhibitor development, and preclinical models and clinical development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)